Meille, Christophe,Wuerthner, Jens,Ferretti, Stephane,Guerreiro, Nelson,Jeay, Sebastien,Jullion, Astrid
申请号：
AU2018242612
公开号：
AU2018242612A1
申请日:
2018.03.29
申请国别(地区):
AU
年份:
2019
代理人:
摘要：
The present invention relates to the HDM2-p53 interaction inhibitors (S)-5-(5-Chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one (HDM201), or a pharmaceutically acceptable non-covalent derivative thereof, for use in the treatment of patients with hematological tumors, wherein the drug is administered by an extended low dose dosing regimen.
